Related Experiment Video
Updated: Mar 27, 2026
07:04
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
1.3K
A High-Throughput Screening Platform Targeting PDLIM5 for Pulmonary Hypertension
Han Cheng1, Tianji Chen2, Merve Tor2
1Department of Microbiology and Immunology, College of Medicine University of Illinois at Chicago, Chicago, IL, USA.
Journal of Biomolecular Screening
|January 15, 2016
Summary
Researchers developed a new screening platform to find drugs targeting PDLIM5, a protein involved in pulmonary hypertension. They identified paclitaxel as a potential inhibitor, offering a new avenue for treating this complex lung disease.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Pulmonary arterial hypertension (PAH) is a complex disease with various causes.
- PDLIM5, a protein in the Enigma subfamily, plays a role in hypoxia-induced PAH.
- Previous studies indicate PDLIM5 may be a therapeutic target for PAH.
Purpose of the Study:
- To establish a high-throughput screening platform for discovering drugs that target PDLIM5.
- To identify novel inhibitors of PDLIM5 for potential PAH treatment.
Main Methods:
- Generated a stable mink lung epithelial cell line (MLEC) with suppressed PDLIM5 (MLEC-shPDLIM5) and a TGF-β/Smad luciferase reporter.
- Measured Smad2/3 and pSmad2/3 levels in MLEC-shPDLIM5 cells.
- Screened the Prestwick library (1200 compounds) using MLEC-shPDLIM5 and MLEC-shCTL cell lines.
- Validated paclitaxel as a PDLIM5 inhibitor and assessed its effects on Smad signaling in A549 cells.
Main Results:
- Suppression of PDLIM5 in MLEC decreased Smad-dependent luciferase activity, Smad3, and pSmad3 levels.
- Paclitaxel was identified as a PDLIM5 inhibitor in MLEC.
- Paclitaxel inhibited Smad2 expression and Smad3 phosphorylation in A549 cells.
Conclusions:
- The developed screening system is robust and suitable for PDLIM5-targeted drug discovery.
- Paclitaxel shows potential as a therapeutic agent for pulmonary hypertension by inhibiting PDLIM5 signaling.
- This platform facilitates the identification of novel drug candidates for PAH.
